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Abstract
Background: Fetal development largely depends on thyroid hormone availability and proper placental function
with an important role played by placental mitochondria. The biological mechanisms by which thyroid hormones
exert their effects on mitochondrial function are not well understood. We investigated the role of fetal thyroid
hormones on placental mitochondrial DNA (mtDNA) content and mtDNA methylation. We collected placental
tissue and cord blood from 305 mother–child pairs that were enrolled between February 2010 and June 2014 in
the ENVIRONAGE (ENVIRonmental influence ON early AGEing) birth cohort (province of Limburg, Belgium). Placental
mtDNA content was determined by qPCR and placental mtDNA methylation by bisulfite-pyrosequencing in two
regions, i.e., the D-loop control region and 12S ribosomal RNA (MT-RNR1). The levels of free thyroid hormones (FT3,
FT4) and thyroid-stimulating hormone (TSH) were measured in cord blood.
Results: Cord blood FT3 and FT4 were inversely associated with placental mtDNA methylation at the MT-RNR1
(p ≤ 0.01) and D-loop (p ≤ 0.05) regions, whereas a positive association was observed for both hormones with
placental mtDNA content (p≤ 0.04). Assuming causality, we estimated that MT-RNR1 and D-loop methylation mediated,
respectively, 77% [indirect effect +14.61% (95% CI 2.64 to 27.98%, p = 0.01)] and 47% [indirect effect +8.60%
(95% CI 1.23 to 16.50%, p = 0.02] of the positive association between FT3 and placental mtDNA content. Mediation
models with FT4 gave similar results but the estimated effect proportions were smaller compared with those of FT3
(54% and 24%, respectively).
Conclusions: We showed that epigenetic modification at specific loci of the mitochondrial genome could intervene
with the thyroid-dependent regulation of mitochondrial DNA copy numbers.
Keywords: DNA methylation, Epigenetics, Mitochondria, Mitochondrial DNA content, Placenta, Fetal thyroid hormones
Background
Thyroid hormones are known to have profound effects
on mitochondrial energetics and biogenesis [1, 2]. Under
the control of thyroid-stimulating hormone (TSH), the
thyroid gland produces thyroxine (T4), the major form
of thyroid hormone, and triiodothyronine (T3), the active
form. On account of its biological activity, unbound or
free T3 (FT3) regulates mitochondriogenesis most likely
in two different cell compartments: (i) binding of FT3 to
thyroid receptors (TRs) that consecutively bind to re-
sponse elements in the nucleus, activating the expression
of mitochondria-related genes such as peroxisome prolif-
erator-activated receptor γ-coactivator1α (PPARGC1A) or
(ii) direct binding to specific TRs in the mitochondrial
matrix stimulating transcription of the mitochondrial
genome [3].
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The placenta is a relevant tissue to investigate the
interplay between thyroid hormones and mitochondria.
This metabolically active organ contains a high number
of mitochondria and regulates nutrient, oxygen, and
hormonal transfer, allowing for fetal growth. It is also
well established that thyroid hormones are critical for
placental [4] and fetal development [5]. FT3 stimulates
the production of factors that control trophoblast
growth and development [6]. The placenta expresses
two types of iodothyronine deiodinases (D2 and D3)
that are capable of metabolizing FT4 to FT3 [7], and
thus, plays an important role in thyroid hormone
homeostasis.
Although some studies are questioning the presence of
DNA methylation in the mitochondrial genome [8, 9],
in the last few years, mtDNA methylation has emerged
as a next-generation biomarker that might be a diag-
nostic tool for several diseases such as cardiovascular
disease [10]. Here, we examined two specific mtDNA
loci, i.e., the displacement loop (D-loop) and MT-
RNR1. DNA methylation levels in the D-loop control
region are suggested to play an important role in
modulating either the replication or transcription of
mtDNA since nearly the entire mitochondrial genome
transcribes from this region [11]. Our other studied
locus MT-RNR1 encodes for the 12S rRNA protein
which is critical for normal function and integrity of
the mitochondrial ribosome [12]. In this mother–newborn
study, we aimed to elucidate possible mechanisms in-
volved in the regulation of mitochondrial biogenesis by in-
vestigating the association between fetal FT3, FT4, and
TSH with mtDNA content and mtDNA methylation in
placental tissue. We hypothesized that methylation at spe-
cific loci of the mitochondrial genome could interfere with
thyroid hormone-dependent regulation of mitochondrial
biogenesis.
Results
Mother–newborn characteristics and demographics
The study included 305 mother–child pairs (mean ma-
ternal age, 29.1 yr; range, 18–42 years). Demographic
and prenatal lifestyle factors are reported in Table 1.
Briefly, mean (10th–90th percentile) pre-pregnancy body
mass index (BMI) of the participating mothers was 24.1
(19.7–29.7) kg/m2. Fifty-two mothers (17.1%) reported to
have smoked during pregnancy and smoked on average
7.8 cigarettes per day. Most women (64.9%, n = 198)
never smoked cigarettes. The majority (>50%) of the
mothers were highly educated. Nearly half of the new-
born population were boys (n = 151; 49.5%). The overall
mean gestational age was 39.2 weeks (10th–90th per-
centile 18–41) and included a vast majority of primipar-
ous (51.8%, n = 158) or secundiparous (36.7%, n = 112)
newborns.
Levels of fetal thyroid hormones, placental mtDNA
methylation, and mtDNA content
The geometric means (10th–90th percentile) of thyroid
hormone levels in cord blood were 2.63 (2.15–3.22)
pmol/L for FT3, 15.66 (13.26–18.53) pmol/L for FT4,
and 11.65 (5.16–20.59) mU/L for TSH (Table 2). A posi-
tive correlation was observed between the FT3 and FT4
Table 1 Characteristics of mother–child pairs (n = 305)
Characteristics Mean (10th–90th percentile)
or frequency (%)
Mother
Age, years 29.1 (23–36)
Pre-pregnancy BMI, kg/m2 24.1 (19.7–29.7)






Never smoker 198 (64.9%)
Cessation before pregnancy 55 (18.0%)










Gestational age, weeks 39.2 (38–41)
Season at delivery
Winter (Dec–Mar) 80 (26.2%)
Spring (Mar–Jun) 89 (29.2%)
Summer (Jun–Sep) 60 (19.7%)
Autumn (Sep–Dec) 76 (24.9%)
Apgar score after 5 min
7 or 8 20 (6.6%)
9 90 (29.5%)
10 195 (63.9%)
Cord plasma insulin, pmol/L* 46.4 (15.3–85.4)
Birth weight, g 3421 (2880–3985)
aMother’s education: low (no high school diploma), middle (high school
diploma), high (college or university diploma)
bBased on the native country of the newborn’s grandparents. European-
Caucasian when two or more grandparents were European, or non-European
when at least three grandparents were of non-European origin
*Geometric mean
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values (r = 0.25; p < 0.0001) and between the FT3 and
TSH values (r = 0.19; p = 0.0008) (Fig. 1).
Table 2 also shows mtDNA methylation and mtDNA
content values measured in placental tissue. Placental
mtDNA methylation averaged (10th–90th percentile)
9.51% (4.46–14.67) for MT-RNR1 and 3.61% (1.94–5.24)
for D-loop. The methylation levels of MT-RNR1 and D-
loop were strongly correlated (r = 0.85, p < 0.0001) (Fig. 1
and Additional file 1: Figure S1). The geometric mean of
placental mtDNA content was 1.11 (0.49–2.49) (unitless).
In this subset, and as previously published [13], we report
a strong inverse correlation between placental mtDNA
methylation and mtDNA content (r = −0.63, p < 0.0001 for
MT-RNR1 and r = −0.40, p < 0.0001 for D-loop) (Fig. 1).
Association of fetal thyroid hormones with placental
mtDNA methylation and mtDNA content
Both fetal FT3 and FT4 were inversely correlated with
mtDNA methylation at the MT-RNR1 and D-loop region,
whereas a positive correlation was observed for both hor-
mones with mtDNA content in placental tissue (see Fig. 1
for correlations). Fetal TSH levels did not correlate with
either placental mtDNA methylation or mtDNA content.
The associations remained significant after adjustment
for maternal age, pre-pregnancy BMI, gestational age,
newborn’s sex, smoking status, parity, maternal education,
ethnicity, and cord plasma insulin level. A 10th–90th per-
centile increment (53%) in cord blood FT3 (log10 values)
was associated with a lowering in absolute methylation of
−1.50% (95% CI −2.70 to −0.30%, p = 0.01) for MT-RNR1
and −0.46% (95% CI −0.83 to −0.09%, p = 0.02) for D-loop.
A similar association, but with smaller estimates, was ob-
served for FT4 (Table 3). On the other hand, a 10th–90th
percentile increment in cord blood FT3 (53%) or FT4
(13%) was associated with a higher placental mtDNA con-
tent (relative change) of +20.35% (95% CI 0.47 to 44.17%,
p = 0.04) for FT3 and +11.04% (95% CI 4.00 to 18.54%, p =
0.002) for FT4.
Mediation analysis
We performed mediation analysis to estimate the pro-
portion of the associations between cord blood thyroid
hormones and placental mtDNA content that might be
mediated by changes in mtDNA methylation if the
underlying causal assumptions of the mediation analysis
are valid. We selected both MT-RNR1 and D-loop as po-
tential mediators because methylation levels at both re-
gions were significantly associated with FT3 and FT4 as
well as with placental mtDNA content (Fig. 1). While
adjusting for the aforementioned variables, we estimated
that MT-RNR1 methylation mediated 77% [indirect ef-
fect +14.61% (95% CI 2.64 to 27.98%, p = 0.01)] and D-
loop methylation mediated 47% [indirect effect +8.60%
Table 2 Cord blood thyroid hormone levels and placental mtDNA content and mtDNA methylation
Mean SD 10th percentile 90th percentile
Thyroid hormonesa
FT3, pmol/L 2.63 0.47 2.15 3.22
FT4, pmol/L 15.66 2.08 13.26 18.53
TSH, mU/L 11.65 7.60 5.16 20.59
mtDNA methylationb
MT-RNR1, % 9.51 4.19 4.46 14.67
D-loop, % 3.61 1.31 1.94 5.24
mtDNA content (unitless)b,c 1.11 0.96 0.49 2.49
Values are presented as geometric means with 10th-90th percentiles, except for mtDNA methylation for which the arithmetic mean is given
aLaboratory reference values for adults range from 4.0 to 6.8 pmol/L for FT3, from 12.0 to 21.9 pmol/L for FT4, and from 0.3 to 4.2 mIU/L for TSH
bMeasured in placental tissue
cDetermined as the ratio of two mitochondrial genes gene copy numbers (MTF3212/R3319 and MT-ND1) to two single-copy nuclear control genes (RPLP0 and ACTB)
Fig. 1 Unadjusted correlation matrix between thyroid hormones
(FT3, FT4, TSH), mtDNA methylation (MT-RNR1, D-loop), and mtDNA
content. Numbers represent Pearson correlation coefficients and only
the colored boxes are significant correlations at p-level < 0.05 (red:
positive significant correlation; blue: negative significant correlation;
blank: not-significant)
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(95% CI 1.23 to 16.50%, p = 0.02)] of the positive associ-
ation between FT3 and placental mtDNA content (Fig. 2).
Mediation models with FT4 gave similar results but the
estimated effect proportions were smaller compared
with those of FT3 (54 and 24%, respectively) (Additional
file 1: Figure S2).
Sensitivity analysis
Certain CpGs were more associated with fetal thyroid
hormones compared to others, underscoring the import-
ance of methylation levels at specific CpG (Additional
file 2: Table S1). For example, FT3 was associated with
methylation levels at all three CpG sites of D-loop (the
transcription start site of the mitochondrial genome).
Excluding women who had undergone a cesarean sec-
tion (n = 13) slightly increased our effect estimates for
FT3 (Additional file 2: Table S2), whereas excluding small
for gestational age infants (n = 22) slightly decreased our
effect estimates for FT3 (Additional file 2: Table S3). How-
ever, we verified whether the association between fetal thy-
roid hormones and placental mtDNA content was still
present in the initial group of 547 mother–child pairs
(flowchart Additional file 1: Figure S3). Adjusting for the
aforementioned variables, the association between cord
blood FT3 and placental mtDNA content was stronger
compared with the reported association in the main
analysis, i.e., relative change of +29.22% (95% CI
16.22 to 43.67%, p < 0.0001) for a 10th–90th percent-
ile increment in cord blood FT3, whereas the associ-
ation for FT4 was less (+6.65%, 95% CI 2.23 to
11.26%, p = 0.003).
Furthermore, additional adjustments for cord blood
plasma estradiol (n = 304), passive indoor tobacco smoke
exposure (n = 295), alcohol consumption (n = 295), or
pH of the arterial cord blood (indicator of hypoxemia)
(n = 264), did not alter our associations between fetal
thyroid hormones and mtDNA content or mtDNA
methylation (data not shown).
Mitochondrial biogenesis relies on a tightly coordi-
nated process between the nuclear and mitochondrial
genome. For example, the nuclear gene PPARGC1A is a
central regulator of mitochondrial gene expression and
biogenesis that is also controlled by FT3 [14]. We observed
an inverse association between fetal FT3 levels and placen-
tal PPARGC1A promoter methylation, i.e., −2.31% (95% CI
−4.04 to −0.59, p = 0.009) for a 10th–90th percentile incre-
ment in FT3 (Additional file 2: Table S1). No association
was observed between placental PPARGC1A promoter
Table 3 Associations of placental mtDNA methylation and content with cord blood thyroid hormones
FT3, pmol/L FT4, pmol/L TSH, mU/L
Variable β (95% CI) β (95% CI) β (95% CI)
mtDNA methylationa
MT-RNR1 -1.50 (-2.70 to -0.30)* -0.60 (-1.04 to -0.16)* 0.38 (-0.21 to 0.97)
D-loop -0.46 (-0.83 to -0.09)* -0.14 (-0.28 to -0.002)* 0.11 (-0.07 to 0.29)
mtDNA contentb 20.35 (0.47 to 44.17)* 11.04 (4.00 to 18.54)** -5.34 (-13.35 to 3.40)
aβ represents an absolute change in placental mtDNA methylation percentage (%) for a 10th-90th percentile increment of cord blood thyroid hormone
bβ represents a relative change (%) in placental mtDNA content for a 10th-90th percentile increment of cord blood thyroid hormone
All models are adjusted for maternal age, pre-pregnancy BMI, gestational age, newborn’s sex, smoking status, parity, maternal education, ethnicity, and cord
plasma insulin level
*p-value < 0.05, **p-value < 0.005
Fig. 2 Estimated proportion of effects of FT3 exposure on mtDNA content mediated by mtDNA methylation. The figure displays placental mtDNA
methylation as mediator (left panel: MT-RNR1; right panel: D-loop), the estimates of indirect effect (IE), the estimates of the direct effect (DE), and
proportion of mediation (IE/DE + IE). The effects represent a relative change (%) in placental mtDNA content for an increment between the 10th-90th
percentile of FT3. All models were adjusted for maternal age, pre-pregnancy BMI, gestational age, newborn’s sex, smoking status, parity, maternal
education, ethnicity, and cord plasma insulin level. *p-value < 0.05
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methylation and mtDNA content (p = 0.23) or mtDNA
methylation (D-loop, p = 0.54;MT-RNR1, p = 0.74).
Discussion
In this study, we report for the first time associations
between fetal thyroid hormones and epigenetic modi-
fication at specific loci in the mitochondrial genome
that could, at least in part, mediate the fetal thyroid-
dependent regulation of mitochondrial biogenesis in
placental tissue.
From mid-gestation onwards, the fetus starts secreting
small amounts of thyroid hormones in addition to the
transplacental supply of maternal thyroid hormones
[15]. The optimal concentration of fetal thyroid hor-
mones at each stage of development is maintained by
the placenta, in conjunction with the fetal thyroid gland,
liver, and kidneys [4]. The placenta expresses two types
of iodothyronine deiodinases (D2 and D3) that are cap-
able of metabolizing FT3 and FT4 [7], and thus, plays an
important role in thyroid hormone homeostasis. Besides
regulating fetal development [5], thyroid hormones have
profound effects on mitochondrial energetics and bio-
genesis [1, 2].
Despite the spectacular progress in the knowledge of
the T4-T3 nuclear pathway, a clear answer to how it
regulates mitochondrial biogenesis is lacking. While it
is known that an upregulation of nuclear-encoded re-
spiratory genes including PPARGC1A occurs within
hours after injection of T3 in hypothyroid rats, other
non-genomic direct effects are detectable within minutes
suggesting another mode of action [16, 17]. T3 binds
directly to specific receptors inside the mitochondria. A
43 kDa c-Erb A alpha1 protein (p43), located exclusively in
the mitochondrial matrix, acts as a T3-dependent transcrip-
tion factor and specifically binds to four mitochondrial
DNA sequences with a high similarity to nuclear T3 re-
sponse elements [18, 19]. Overexpression of p43 increases
mitochondrial genome transcription and protein synthesis,
stimulating mitochondrial biogenesis in a T3-dependent
manner [19]. Interestingly, of the four mitochondrial DNA
sequences, two response elements are located in the D-loop
region and one in the MT-RNR1 gene. We hypothesized
that DNA methylation at these mitochondrial hotspots
could interfere with thyroid hormone-dependent regulation
of mitochondrial biogenesis. First, we have shown that fetal
thyroid hormones, especially FT3, are positively associated
with placental mtDNA content and inversely associated
with placental methylation levels at the D-loop and MT-
RNR1 region. Next, we underscored a substantial mediating
role of placental mtDNA methylation between the associ-
ation of fetal thyroid hormones and placental mtDNA con-
tent. Hence, we postulate that high DNA methylation levels
in the mitochondrial genome are related to conformational
or structural changes making the mtDNA less accessible to
proteins and transcription factors such as the T3-dependent
transcription factor p43. Previously, we have shown that ex-
posure to particulate matter (PM2.5) during pregnancy is as-
sociated not only with changes in fetal thyroid hormones
[20] but also with higher levels of methylation of the D-loop
and the MT-RNR1 sequence, affecting mtDNA content in
placental tissue [13]. An increase in mtDNA methylation
was observed in blood leukocytes of steel workers exposed
to air pollution [21] and in an experimental study of human
cultured cells treated with ethidium bromide [22]. The
ethidium-bromide-exposed cells recovered from mtDNA
depletion and showed increased overall methylation levels
indicating that mtDNA was less packed with proteins dur-
ing active mtDNA replication [22].
Our mediation analysis revealed that the effect of FT3
on mtDNA content is mediated for 77% by MT-RNR1
and for 54% by D-loop methylation levels, meaning that
there are alternative routes, most likely nuclear path-
ways, by which thyroid hormones exert their action on
mitochondrial biogenesis. T3 controls the expression of
PPARGC1A [16], a transcriptional co-activator of several
nuclear-encoded transcription factors including mito-
chondrial transcription factor A (TFAM) that regulates
mitochondrial biogenesis [23] (Fig. 3). In addition to
specific mitochondrial actions of FT3, we also observed
an inverse association between placental PPARGC1A
promoter methylation and fetal FT3 levels. Most likely
this is indicative of upregulated PPARGC1A mRNA
levels in the presence of high FT3 concentrations since
promoter hypomethylation is usually associated with in-
creased gene expression due to unwound DNA that is
available for transcription factors. Interestingly, our in-
terrogated region is a putative binding site for CREB
transcription factors. The transcriptional activity of CREB
is critical for the establishment and maintenance of energy
homeostasis in mice neonates [24] and appears to be
involved in the regulation of PPARGC1A. It is noteworthy
to mention that the promoter region of PPARGC1A was
largely unmethylated in cord blood but not in placental tis-
sue [25], suggesting differential regulation of PPARGC1A in
cord blood and placental tissue. Even though nuclear-
encoded genes that are involved in mitochondrial function
are regulated by epigenetic mechanisms [26], it would be
interesting to determine the direct functional signifi-
cance at mRNA expression level in response to FT3
levels. Unfortunately, we did not measure mRNA ex-
pression due to lack of suitable RNA samples and con-
sider this a limitation of the study. We also have no
clear information on “threshold” changes in mtDNA
methylation that lead to functional effects of mitochon-
driogenesis. The mitochondrial genome, as far as we
observed, shows a far less DNA methylation level (range 0
to 40%) compared with nuclear DNA (range 0 to 100%).
Hence, small changes in mtDNA methylation might still
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have functional effects. It has been shown that small
changes in single CpG sites and regional methylation
changes interfere with gene/protein expression [27] by al-
tering the affinity of transcription factors to their binding
sites or chromosome looping events [28]. Even when small
changes in methylation would not impact functional ef-
fects, mtDNA methylation can provide invaluable help in
developing new and useful markers of exposure and dis-
ease [29]. However, our findings should first be confirmed
in an experimental study and we need to investigate the
health consequences in later life before we can translate it
into a clinical meaning.
We are aware of the issue of placental tissue hetero-
geneity but it is difficult to assess the impact of this vari-
ation on our methylation results. To our knowledge,
there is only one study that explored genome-wide DNA
methylation patterns in the two main cell types of the
placenta (cytotrophoblasts and fibroblasts) [30]. These cell
types did not demonstrate genome-wide differentiation in
DNA methylation but some specific genes showed dif-
ferential promoter methylation. Although these authors
demonstrated that the methylation profile of the pla-
centa is mainly driven by cytotrophoblasts, there is a
possibility that our epigenetic data is confounded by
variation in cell type distributions. To overcome this
obstacle, one should correct for differences in tissue
composition using algorithms that estimate cell type
proportions based on DNA methylation signatures de-
rived from Illumina microarrays [31, 32]. However, stat-
istical adjustments of DNA methylation data for cell
distributions require the availability of reference epi-
genomes for the component cell types created by cell
sorting [33]. Currently, there is no algorithm available
to estimate the cell type proportions in placental tissue.
Another limitation of our study is that we were not
able to measure thyroid hormones in placental tissue
Fig. 3 Simplified scheme of T3-dependent mitochondrial biogenesis through coordinated regulation of nuclear and mitochondrial gene products.
T3 binds to thyroid receptors (TRs) (1) which consecutively bind to response elements in the nucleus activating expression of mitochondrial-related
genes such as PPARGC1A (2). Alternatively, specific TRs are localized in the mitochondrial matrix (p43). The T3-p43 complex binds to response elements
in the mitochondrial genome, of which two elements are located in the D-loop and one in the 12S rRNA (MT-RNR1) gene (3). We suggest that
methylation of the mtDNA genome, in particular in the D-loop and MT-RNR1 region, could intervene with T3-dependent mitochondrial protein
production through conformational or structural changes making the mtDNA less accessible to proteins and transcription factors such as the
T3-dependent transcription factor p43 (4)
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but we used cord blood levels as a proxy since it circu-
lates through the fetal side of the placenta.
Conclusions
Given our epidemiological findings and other experimen-
tal research data, it seems that there exist coordinated
events between mtDNA methylation, mtDNA content,
and thyroid hormones. We summarized our findings in a
simplified scheme (Fig. 3) indicating that epigenetic modi-
fication at specific loci of the mitochondrial genome could
intervene with thyroid-dependent regulation of mitochon-
drial biogenesis. Our findings could contribute to further
epidemiological understanding of mitochondrial disorders.
Whether alterations in mitochondrial function or new-
born’s thyroid hormone levels have health conse-
quences later in life should be elucidated.
Methods
Study population
Within the on-going ENVIRONAGE birth cohort
(ENVIRonmental influence ON early AGEing) [34], we
conducted our investigation in a group of 589 singleton
pregnancies for which the mothers agreed withdrawal of
cord blood, the collection of the placenta after delivery,
and the use of information from their medical files. The
placenta could not be collected for ten newborns, four pla-
centas had insufficient DNA yield, 12 placentas had miss-
ing measurements of mtDNA content, and 16 mothers
with thyroid gland complications were excluded. Because
mtDNA methylation was measured only in a subset of this
large study sample (n = 547), we ended with a final sample
size of 305 newborns for the main analysis (see flowchart;
Additional file 1: Figure S3).
Mother-child pairs were recruited from February 2010
to June 2014 at the East-Limburg Hospital in Genk
(Belgium) following procedures approved by the Ethical
Committee of Hasselt University and the East-Limburg
Hospital and according to the principles outlined in the
Helsinki Declaration for investigation of human subjects
as previously described in details [35]. Briefly, written in-
formed consent was obtained from eligible participants
before delivery. Questionnaires and medical records
consulted after birth provided information on maternal
age, maternal education, smoking status, ethnicity, pre-
pregnancy BMI, gestational age, newborn’s sex, Apgar
scores, birth weight and length, parity, and ultrasono-
graphic data. Information about maternal tobacco smoke
exposure was obtained by asking whether mothers
smoked during pregnancy, whether they smoked at any
time during their life, or if they never smoked in their life.
All neonates were assessed for congenital anomalies im-
mediately after birth and were considered healthy with an
Apgar score after 5 min ranging between 7 and 10. No
neonate was delivered in the Neonatal Intensive Care
Unit. The ENVIRONAGE birth cohort generally consists
of mothers with normal pregnancies without complica-
tions and with healthy neonates.
Cord blood collection and thyroid hormones
measurements
Immediately after delivery, the umbilical cord was clamped
and cord blood was drawn in plastic BD Vacutainer® Lith-
ium Heparin Tubes (BD, Franklin Lakes, NJ, USA). Blood
tubes were centrifuged at 3200 rpm for 15 min to retrieve
plasma which was instantly kept at −80 °C. FT4 (pmol/L),
FT3 (pmol/L), TSH (mU/L), and insulin were measured in
plasma using an electro-chemiluminescence immuno-
assay using the Modular E170 automatic analyzer
(Roche, Basel, Switzerland) at the clinical lab of East-
Limburg Hospital.
Placental collection
Placentas were deep-frozen within 10 min of delivery,
and afterwards, placental specimens were taken for DNA
extraction after minimally thawing of the placentas. We
took villous tissue (1 to 2 cm3) at a fixed location from the
fetal side of the placenta, approximately 1–1.5 cm below
the chorio-amniotic membrane, and preserved the biop-
sies at −80 °C [25]. Genomic DNA was isolated from pla-
cental tissue using the QIAamp DNA mini kit (Qiagen,
Inc., Venlo, the Netherlands) and stored at −80 °C until
further use.
DNA methylation analyses
In 305 placentas, we performed DNA methylation ana-
lysis by highly quantitative bisulfite-PCR pyrosequencing
as previously described [25]. Briefly, bisulfite conversions
were performed using 1 μg of extracted genomic DNA
with the EZ-96 DNA methylation Gold kit (Zymo Re-
search, Orange, CA, USA) according to the manufacturer’s
instructions. We interrogated CpG sites within specific
regions of the mitochondrial genome (MT-RNR1 and
D-loop) and the promoter of PPARGC1A as described
by Byun et al. [21] and Janssen et al. [25]. Detailed infor-
mation regarding primer sequences is given in Additional
file 2: Table S4. PCR amplification of regions of interest
prior to pyrosequencing was performed in a total reaction
volume of 30 μl, using 15 μl GoTaq Hot Start Green Mas-
ter Mix (Promega, Madison, WI, USA), 10 pmol forward
primer, 10 pmol reverse primer, 1 μl bisulfite-treated gen-
omic DNA, and water. PCR products were purified and
sequenced by pyrosequencing using the PyroMark Q96
MD Pyrosequencing System (Qiagen, Inc., Germantown,
MD, USA). The degree of methylation was expressed as
the percentage of methylated cytosines over the sum of
methylated and unmethylated cytosines. Samples were
run in duplicate on two different plates from which the
average methylation levels were used. The coefficient of
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variation was 3.7% for MT-RNR1, 5.8% for D-loop, and
8.1% for PPARGC1A. The efficiency of the bisulfite-
conversion process was assessed using non-CpG cytosine
residues within the sequence. We used 0% (PSQ-T oligo:
5′-TTGCGATACAACGGGAACAAACGTTGAATTC-3′)
and 100% (PSQ-C oligo: 5′-TTGCGATACGACGGGAAC
AAACGTTGAATTC-3′) DNA methylation control oligos.
The sequencing primer for the control oligo was 5′-
AACGTTTGTTCCCGT-3′. We mixed the PSQ-C oligo
(or PSQ-T oligo) with the sequencing oligo in PyroMark
Annealing Buffer (Qiagen, Inc., Valencia, CA, USA) and
performed pyrosequencing with the sequencing entry
C/TGTAT. The between- and within-placenta variability,
exemplified by the intra-class correlation coefficient,
was evaluated in a subset of 19 placentas and was 58
vs. 42% (p = 0.009) for MT-RNR1, 61 vs. 39% (p = 0.01)
for the D-loop region and 64 vs. 36% (p = 0.005) for
PPARGC1A [25].
mtDNA content analysis
mtDNA content was measured in placental tissue by de-
termining the ratio of two mitochondrial gene copy
numbers (MTF3212/R3319 and MT-ND1) to two single-
copy nuclear control genes (RPLP0 and ACTB) using a
quantitative real-time polymerase chain reaction (qPCR)
assay as previously described [35] but with small modifi-
cation. Briefly, 2.5 μl diluted genomic DNA (5 ng/μl)
was added to 7.5 μl mastermix consisting of Fast SYBR®
Green I dye 2× (5 μl/reaction), forward and reverse pri-
mer (each 0.3 μl/reaction), and RNase free water (1.9 μl/
reaction). Primer sequences (Additional file 2: Table S5)
were diluted to a final concentration of 300 nM in the
master mix. Samples were run in triplicate in 384-well
format. Real-time PCR was performed using the 7900HT
Fast Real-Time PCR System (Applied Biosystems, Foster
City, CA, USA) with the following thermal cycling profile:
20 s at 95 °C (activation), followed by 40 cycles of 1 s at
95 °C (denaturation) and 20 s at 60 °C (annealing/exten-
sion), ending with melting curve analysis (15 s at 95 °C,
15 s at 60 °C, 15 s at 95 °C). qBase software (Biogazelle,
Zwijnaarde, BE) was used to normalize data and correct
for run-to-run differences [36].
Statistical analysis
For database management and statistical analysis, we
used the SAS software program (version 9.4; SAS Insti-
tute Inc., Cary, NC, USA). mtDNA content and thyroid
hormone levels were log10-transformed to improve nor-
mality. For each subject, we measured in placental tissue
methylation levels of CpG sites at two regions of the
mitochondrial genome and at the promoter region of
PPARGC1A. The pyrosequencing-based DNA methyla-
tion analysis produced a methylation value (%) for each
CpG of MT-RNR1 (two CpGs), the D-loop region (three
CpGs), and PPARGC1A (three CpGs). In the main ana-
lysis, we used the average methylation levels of the dif-
ferent CpGs. Pearson correlation coefficients were
calculated between the different thyroid hormone levels
in cord blood (FT3, FT4, and TSH), mtDNA methyla-
tion (MT-RNR1 and D-loop), and mtDNA content in
placental tissue using R software packages. We per-
formed multiple linear regression to determine the as-
sociation between thyroid hormones and placental
mtDNA methylation (both MT-RNR1 and D-loop) and
between thyroid hormones and placental mtDNA con-
tent. Thyroid hormones were fitted as linear variables
in the models, and effect estimates on mtDNA methy-
lation and mtDNA content were calculated for a
10th–90th percentile increment in thyroid hormones,
which corresponds to a 52% change in FT3, a 12%
change in FT4, and a 84% change in TSH. All models
were adjusted for maternal age, pre-pregnancy BMI,
gestational age, newborn’s sex, smoking status, parity,
maternal education, ethnicity, and cord plasma insulin
level. The Shapiro-Wilk statistic and Q-Q plots of the
residuals were used to test the assumptions of all linear
models.
We used mediation analysis to investigate potential as-
sociations that may underlie the relation between the ex-
posure variable (FT3 or FT4) and the continuous outcome
variable (mtDNA content) by examining how they relate
to a third variable, the mediator (mtDNA methylation)
[37]. We accomplished this by decomposing the total ef-
fect into a direct effect (DE; exposure effect on outcome at
a fixed level of the mediator) and an indirect effect (IE;
exposure effect on outcome that operates through the
mediator).
Sensitivity analysis
To underscore the importance of single CpG sites, we
performed separate linear regression analyses between
levels of FT3 or FT4 and the methylation levels at each
CpG site of MT-RNR1 and D-loop. Furthermore, it is
known that cord blood thyroid hormone levels are influ-
enced not only by different external factors such as fetal
stress exemplified by cesarean section [38] but also by
other factors such as cord plasma estradiol [39], passive
smoking [40], alcohol consumption [41], and pH of ar-
terial cord blood [42]. Besides adjusting the main model
with the aforementioned variables, we performed add-
itional analyses in which we excluded women who had
undergone a cesarean section or excluding infants born
with a birth weight less than the 10th percentile. Lastly,
we used linear regression analyses to investigate the as-
sociation between fetal thyroid hormones and placental
promoter methylation of the nuclear gene PPARGC1A.
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